Comparison of two cotside methods for the detection of hypoglycaemia among neonates in Nepal

M Ellis, D S Manandhar, N Manandhar, J M Land, N Patel, A M de L Costello

Abstract

Aims—To compare two cotside methods of blood glucose measurement (HemoCue and Refractolux II) against a standard laboratory method for the detection of neonatal hypoglycaemia in a developing country maternity hospital where hypoglycaemia is common.

Methods—94 newborn infants and 75 of their mothers had blood glucose assessed on the same venous sample using three different methods in the Special Care Baby Unit and postnatal wards, Prasuti Griha Maternity Hospital, Kathmandu, Nepal: HemoCue and Refractolux II at the cotside; Roche Ultimate glucose oxidase method (GOM) in the laboratory.

Results—The mean (SD) values for blood glucose in newborn infants were GOM 2.5 (1.1) mmol/l; Refractolux II 2.1 (0.9); and HemoCue 4.2 (1.2). For mothers the values were GOM 5.3 (1.2) mmol/l; Refractolux II 3.6 (1.2); and HemoCue 5.6 (1.0). Bland–Altman plots showed that Refractolux II consistently underreads GOM blood glucose in neonates by 0.5 mmol/l (SD 0.7) and that HemoCue overreads glucose by 1.7 mmol/l (SD 0.8). For the detection of hypoglycaemia (<2.0 mmol/l), Refractolux II achieved a sensitivity of 83%, a specificity of 62%, and a likelihood ratio of 2.2. HemoCue produced a sensitivity of 0% and a specificity of 100% using measured values. If 2.0 mmol/l were subtracted from all Hemocue values this rose to 81% and 68% and a likelihood ratio of 2.5.

Conclusion—Although more accurate than Refractolux II for the measurement of blood glucose in mothers, HemoCue overreads glucose concentrations in neonates and is therefore potentially dangerous as a screening method for neonatal hypoglycaemia. Refractolux II is useful as a screening method for high risk infants (low birth-weight, post-term) and could achieve a post-test probability of detecting hypoglycaemia in a high risk setting like Nepal of 50–60%.

Keywords: hypoglycaemia, blood glucose, Refractolux II, HemoCue, Nepal.

Neonatal hypoglycaemia is a common and neglected problem in many parts of the developing world. An earlier study in the main government maternity hospital in Kathmandu, Nepal, showed that 38% of uncomplicated term infants experienced mild (blood glucose <2.6 mmol/l) and 8% moderate/severe (<2.0 mmol/l) hypoglycaemia during the first 48 hours. Infants requiring special care are even more likely to be at risk of hypoglycaemia as a result of prematurity, being small for gestational age, or because of asphyxia or infection.

In most hospitals in the developing world blood glucose is not screened for at the cotside, and often laboratory facilities for venous glucose analysis are unavailable. A lack of resources and limited awareness of the problem compound this. Two cotside methods for blood glucose, which are potentially practical and low cost, are the Refractolux II BM stix and the HemoCue cuvette. However, doubts have been cast on the validity and reliability of both methods at low blood sugar concentrations, when haematocrit concentrations are high, and in a field situation. Few studies have used appropriate statistical techniques in method comparison studies: analysis using difference plots and appropriate limits of agreement are preferred to correlation and linear regression.

Our study aimed to compare these two cotside methods of blood glucose measurement against a standard laboratory method, and to estimate their reliability for the detection of neonatal hypoglycaemia in the setting of a maternity hospital in a developing country where hypoglycaemia is known to be common.

Methods

The study was conducted at Prasuti Griha, a large government funded maternity hospital in Kathmandu, Nepal. Nepal is a low income country with an average income of $180 per capita and poor health indicators, including high infant (123/1000 livebirths), and under 5 (189/1000) mortality rates, low female literacy (13%), and only 10% of births attended by a trained attendant.

The hospital, the largest maternity unit in the country, provides 250 beds and outpatient services for over 80 000 attendances each year. Over 14000 patients are delivered annually with about 1800 admissions to the Special Care Baby Unit.

Earlier studies have shown that neonatal hypoglycaemia is common, but lack of staff and equipment mean that only high risk infants can be screened for hypoglycaemia at the
Comparison of cotside methods for detection of hypoglycaemia in neonates

Table 1  Blood glucose (mean, SD, and range) concentrations measured in mothers (n=75) and newborn infants (n=94), and numbers (%) of hypoglycaemic newborns, using two cutoff definitions (< 2.6 and < 2.0 mmol/l), using three different methods of measurement for blood glucose

<table>
<thead>
<tr>
<th>Method</th>
<th>Mothers (n=75) blood glucose</th>
<th>Infants (n=94) blood glucose</th>
<th>No of infants (%) with blood glucose &lt; 2.6 mmol/l</th>
<th>No of infants (%) with blood glucose &lt; 2.0 mmol/l</th>
</tr>
</thead>
<tbody>
<tr>
<td>Laboratory GOM</td>
<td>5.3 (1.2) 5.2</td>
<td>2.5 (1.1) 2.4</td>
<td>58 (62)</td>
<td>31 (33)</td>
</tr>
<tr>
<td>Reflolux II</td>
<td>3.0-8.3</td>
<td>0.4-7.5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reflolux II</td>
<td>3.6 (1.2) 3.6</td>
<td>2.1 (0.9) 1.8</td>
<td>72 (77)</td>
<td>49 (53)</td>
</tr>
<tr>
<td>HemoCue</td>
<td>5.6 (1.0) 5.6</td>
<td>4.2 (1.2) 4.1</td>
<td>3 (3)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>HemoCue: corrected by subtracting</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(a) 1.0 mmol</td>
<td>26% (12-44%)</td>
<td>92% (83-98%)</td>
<td>3.3</td>
<td></td>
</tr>
<tr>
<td>(b) 1.5 mmol</td>
<td>58% (39-75%)</td>
<td>86% (75-95%)</td>
<td>4.1</td>
<td></td>
</tr>
<tr>
<td>(c) 2.0 mmol</td>
<td>81% (63-93%)</td>
<td>68% (55-79%)</td>
<td>2.5</td>
<td></td>
</tr>
</tbody>
</table>

Table 2  Sensitivity, specificity (and 95% confidence intervals), and likelihood ratios for Reflolux II and HemoCue for detection of neonatal hypoglycaemia (< 2.0 mmol/l measured using laboratory GOM)

<table>
<thead>
<tr>
<th>Cotside method</th>
<th>Sensitivity</th>
<th>Specificity</th>
<th>Likelihood ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reflolux II</td>
<td>83% (65-94%)</td>
<td>62% (49-73%)</td>
<td>2.2</td>
</tr>
<tr>
<td>HemoCue</td>
<td>0% (0-6%)</td>
<td>100% (94-100%)</td>
<td></td>
</tr>
<tr>
<td>HemoCue: corrected by subtracting</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(a) 1.0 mmol</td>
<td>26% (12-44%)</td>
<td>92% (83-98%)</td>
<td>3.3</td>
</tr>
<tr>
<td>(b) 1.5 mmol</td>
<td>58% (39-75%)</td>
<td>86% (75-95%)</td>
<td>4.1</td>
</tr>
<tr>
<td>(c) 2.0 mmol</td>
<td>81% (63-93%)</td>
<td>68% (55-79%)</td>
<td>2.5</td>
</tr>
</tbody>
</table>

cotside, and there is no on-site facility for blood glucose measurement in the laboratory. Although breastfeeding is the norm in the hospital, many mothers discard colostrum and there is often a delay in starting breastfeeding until 24 hours of age or later.

Ethical approval for the study was given by the Nepal Health Research Council and the MIRA project executive committee.

Ninety four infants were enrolled consecutively from the general wards and Special Care Baby Unit. Inclusion criteria were any infant in whom screening for blood glucose was considered to be clinically valuable—pre- or post-term, low birthweight, hypothermia. Mothers were enrolled after the study had been explained to them and their verbal permission sought. Seventy five mothers agreed to give a blood sample.

Clinical details of the study infants and their mothers were recorded. Venous blood (about 0.5 ml) was taken from the infants and blood glucose measured immediately at the cotside using both BM 144 stix with the portable Reflolux II meter, and a HemoCue B glucose analyser and cuvettes, batch No UC 075. (The cuvettes had been transported to Nepal on dry ice and stored in the cold.) The HemoCue is a portable photometric system into which whole blood is introduced by capillary action. After lysis of the cells within the cuvette whole blood glucose concentrations are measured using a coupled glucose dehydrogenase reaction performed in a disposable microcuvette. Technical details have been described elsewhere.7 Blood was stored for further analysis in the laboratory. A similar procedure was repeated (when possible) on the infant’s mother.

Blood glucose was measured in the laboratory using the Roche Ultimate glucose oxidase method programmed to run on the Roche Cobas Fara analyser, using the manufacturer’s protocol. Blood samples were stabilised as follows: 400 μl of blood was mixed with an equal volume of freshly prepared 6% perchloracetic acid at the cotside. Samples were immediately stored in a thermost flask containing ice, and then spun at 3000 rpm for 5 minutes within 30 minutes of collection. Supernatant fluids were stored in plastic tubes, labelled, and placed in a -20°C deep freeze. They were subsequently transferred in liquid nitrogen to the United Kingdom for analysis.

As this was a field study the cotside screening results were based on single values for each individual to replicate usual clinical practice. The laboratory standard values were calculated from the mean of duplicate analyses.

Comparisons of the results obtained by each method for both maternal and infant glucose concentrations were made using Bland-Altman difference plots6 for the respective cotside method vs laboratory analysis. Correlations between difference and average values indicated whether the difference changed with the magnitude of the measurement.

The sensitivity, specificity, and likelihood ratio for the detection of neonatal hypoglycaemia (defined as < 2.0 mmol/l measured using the laboratory GOM) was calculated for the two cotside methods. Ninety five per cent confidence intervals were derived from the binomial distribution.

The likelihood ratio for a test result compares the likelihood of that result in patients with disease (in this paper disease is hypoglycaemia < 2.0 mmol/l) with the likelihood of that result in patients without disease. Using clinical estimates of the pre-test probability of neonatal hypoglycaemia in this population, the likelihood ratio was applied to a nomogram for Bayes theorem8 to estimate the post-test probability of detecting hypoglycaemia.

Results

Ninety four infants were studied—42 male (45%) and 52 female (55%). Their mean birthweight was 2.5 kg (range 1.3-3.5); 85 were term infants and nine pre-term. The BM stix value on one infant was not recorded. Seventy five mothers agreed to be bled; their mean age was 21 years (range 15-32).

Table 1 shows the mean, standard deviation, and range for blood glucose concentrations measured by each method in the mothers and infants, and the numbers (and %) of infants with hypoglycaemia defined at two cutoff levels: less than 2.6, and less than 2.0 mmol/litre. Because this was a selected population of neonates considered to be at clinical risk of hypoglycaemia, the prevalence of moderate/severe hypoglycaemia (33%) was considerably higher than that found previously in uncomplicated infants.1

The sensitivity, specificity, and likelihood ratios for Reflolux II and HemoCue for the detection of neonatal hypoglycaemia (< 2.0 mmol/l measured using the laboratory GOM) are shown in table 2.

Figures 1 and 2 show Bland-Altman plots with 95% limits of agreement (broken lines) and regression line of difference on average for neonatal and maternal blood glucose, respectively. For the Reflolux II data on neonates the correlation between difference and average is
hypoglycaemia, although glucose, blood glucose, although the relation is weak. For the HemoCue data, correlation between difference and average is 0.2 (95% CI -0.1 to 0.39, P=0.05), suggesting that the difference increases positively with the magnitude of blood glucose, although the relation is again weak.

For the Refloflux II data on maternal blood there was no correlation between difference and average. For the HemoCue data correlation between difference and average is -0.26 (95% CI -0.46 to -0.03, P=0.03), suggesting that the difference increases negatively with the magnitude of blood glucose, although the relation is weak.

Discussion
In this study Refloflux II was the best bedside screening method for detecting cases of hypoglycaemia, although it produced both false positive and false negative results (sensitivity 83%, specificity 62%, likelihood ratio 2.19). Refloflux II tended to underestimate blood glucose, although this did not happen more at lower glucose concentrations.

How can the clinician interpret this information to improve clinical practice, especially in a setting where hypoglycaemia is common and laboratory tests unavailable? We have shown previously that 8-11% of newborns without complications in the maternity hospital in Kathmandu have moderate or severe hypoglycaemia (< 2.0 mmol/l) during the first 48 hours (unpublished observations). Low birthweight infants have roughly double the odds of hypoglycaemia as do post-term infants. There is, therefore, a pre-test clinical probability of about 20% for hypoglycaemia among low birthweight infants in this setting, and perhaps 30-40% for higher risk low birthweight, post-term infants. These estimates fit the current results which showed a 30% prevalence of hypoglycaemia among a selected group of high risk infants considered to need a blood glucose estimation on clinical grounds alone. Using the nomogram adapted from Fagan,19 based on pre-test probability and the likelihood ratio of the diagnostic test, a Refloflux II test would achieve a post-test probability of about 35-40% for the detection of hypoglycaemia in low birthweight infants and about 50-60% for a high risk infant.

But in all settings clinicians should be cautious. Kirkham and Watkins10 have shown the range of error of reflectance photometers to be wide and recommend that readings that are even slightly low be checked with laboratory estimations.

Although more accurate than Refloflux II for the measurement of blood glucose in mothers, HemoCue was unreliable and potentially dangerous as a screening tool for the detection of neonatal hypoglycaemia. HemoCue overestimated blood glucose at all concentrations. In this setting HemoCue achieved zero sensitivity for the diagnosis of hypoglycaemia and therefore has no value as a screening test. Indeed it would be dangerous to use HemoCue as it would miss most cases.

Why was HemoCue unreliable in this population and setting? The fact that it worked well in mothers but not their newborns measured at

![Graph A](image1.png)

![Graph B](image2.png)

**Figure 1** Bland-Altman difference plots for neonatal blood glucose, with 95% limits of agreement (broken lines) and regression line of difference on average.

**Figure 2** Bland-Altman difference plots for maternal blood glucose, with 95% limits of agreement (broken lines) and regression line of difference on average.
Comparison of cotside methods for detection of hypoglycaemia in neonates

Comparison of cotside methods for detection of hypoglycaemia in neonates may raise triglyceride concentrations may lower the same time would seem to rule out calibration or measurement error, or a fault with the cuvettes arising from transport or storage. Triglyceride concentrations may raise HemoCue readings, and high haematocrit (common in neonates) may impair the capillary uptake in cuvettes, but neither seems to be adequate explanation. Most evaluations of HemoCue have been conducted using adult blood at higher concentrations of blood glucose, and one of the few studies to have tested the method in newborns examined largely normoglycaemic infants.

Two other studies have reported similar findings to this study—that HemoCue results are higher than those produced by a conventional laboratory analyser. Young et al observed that “the absolute concentration measured by HemoCue may be greater than 1.0 mmol/l higher than YSI (Yellow Springs plasma glucose analyser) concentrations even when approaching hypoglycaemic levels.”

The manufacturers of HemoCue have suggested that definitions of hypoglycaemia should be method specific and advise 3.0 mmol/l as a cutoff point for intervention. Re-analysing our data using corrected HemoCue results (subtracting 1.0, 1.5 or 2.0 mmol/l to the recorded value) gave acceptable sensitivity, specificity, and likelihood ratios (table 2) only after 2.0 mmol had been subtracted from the measured value.

On the basis of these results we cannot support the use of HemoCue for cotside screening of neonatal hypoglycaemia unless cutoff points for intervention are significantly raised.

We are grateful to the British Government Overseas Development Administration for their support.